secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001171843-22-007714
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics CSO Susan Kalled departs effective Nov 29, 2022
--------------------------------------------------------------------

- Susan Kalled, PhD, resigned as Chief Scientific Officer on November 29, 2022.
- Entitled to 12 months base salary severance paid in installments over 12 months.
- Eligible for up to 12 months COBRA premium reimbursement, contingent on separation agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322007714/0001171843-22-007714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322007714/f8k_112922.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer